Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brian A Costello

Showing results (81-90 of 112) with videos related to

Pageof 12
Sort By:
Haematologica|December 4, 2025
Inherited DNA repair variants are associated with clonal hematopoiesis and cardiovascular risk in men with metastatic prostate cancerOlisaemeka Ogbue, Yael Kusne, Osama Mosalem, et al.
Urology|February 5, 2026
A Simplified Prediction Tool for Metastasis after Nephrectomy with Venous Tumor Thrombectomy for RCCDaniel S Roberson, Spyridon P Basourakos, John C Cheville, et al.
Blood|October 28, 2017
Single-agent ibrutinib in relapsed or refractory follicular lymphoma: a phase 2 consortium trialNancy L Bartlett, Brian A Costello, Betsy R LaPlant, et al.
European Urology|August 18, 2014
Exosomal miR-1290 and miR-375 as prognostic markers in castration-resistant prostate cancerXiaoyi Huang, Tiezheng Yuan, Meihua Liang, et al.
Nature Communications|April 1, 2026
Whole-proteome phage immunoprecipitation sequencing reveals germ cell tumor-specific immunosignatureM Bakri Hammami, Andrew M Knight, Haidara Kherbek, et al.
European Urology|December 4, 2021
A Clinical Decision Aid to Support Personalized Treatment Selection for Patients with Clinical T1 Renal Masses: Results from a Multi-institutional Competing-risks AnalysisSarah P Psutka, Roman Gulati, Michael A S Jewett, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 26, 2024
Randomized, Double-Blind Phase III Study of Pazopanib Versus Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease After Metastasectomy: ECOG-ACRIN E2810Leonard J Appleman, Se Eun Kim, Wayne B Harris, et al.
Journal of Pain and Symptom Management|May 5, 2025
Olanzapine for Managing Side Effects From Antiangiogenic Tyrosine-Kinase InhibitorsRegina M Koch, Miguel Muniz, Candy S Peskey, et al.
Frontiers in Oncology|April 13, 2023
Development and validation of a unifying pre-treatment decision tool for intracranial and extracranial metastasis-directed radiotherapyRoman Kowalchuk, Trey C Mullikin, William Breen, et al.
Practical Radiation Oncology|February 13, 2022
Development and Internal Validation of a Recursive Partitioning Analysis-Based Model Predictive of Pain Flare Incidence After Spine Stereotactic Body Radiation TherapyRoman O Kowalchuk, Trey C Mullikin, William S Harmsen, et al.
Pageof 12

Showing results (81-90 of 112) with videos related to

Sort By:
Pageof 12
Haematologica|December 4, 2025
Inherited DNA repair variants are associated with clonal hematopoiesis and cardiovascular risk in men with metastatic prostate cancerOlisaemeka Ogbue, Yael Kusne, Osama Mosalem, et al.
Urology|February 5, 2026
A Simplified Prediction Tool for Metastasis after Nephrectomy with Venous Tumor Thrombectomy for RCCDaniel S Roberson, Spyridon P Basourakos, John C Cheville, et al.
Blood|October 28, 2017
Single-agent ibrutinib in relapsed or refractory follicular lymphoma: a phase 2 consortium trialNancy L Bartlett, Brian A Costello, Betsy R LaPlant, et al.
European Urology|August 18, 2014
Exosomal miR-1290 and miR-375 as prognostic markers in castration-resistant prostate cancerXiaoyi Huang, Tiezheng Yuan, Meihua Liang, et al.
Nature Communications|April 1, 2026
Whole-proteome phage immunoprecipitation sequencing reveals germ cell tumor-specific immunosignatureM Bakri Hammami, Andrew M Knight, Haidara Kherbek, et al.
European Urology|December 4, 2021
A Clinical Decision Aid to Support Personalized Treatment Selection for Patients with Clinical T1 Renal Masses: Results from a Multi-institutional Competing-risks AnalysisSarah P Psutka, Roman Gulati, Michael A S Jewett, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 26, 2024
Randomized, Double-Blind Phase III Study of Pazopanib Versus Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease After Metastasectomy: ECOG-ACRIN E2810Leonard J Appleman, Se Eun Kim, Wayne B Harris, et al.
Journal of Pain and Symptom Management|May 5, 2025
Olanzapine for Managing Side Effects From Antiangiogenic Tyrosine-Kinase InhibitorsRegina M Koch, Miguel Muniz, Candy S Peskey, et al.
Frontiers in Oncology|April 13, 2023
Development and validation of a unifying pre-treatment decision tool for intracranial and extracranial metastasis-directed radiotherapyRoman Kowalchuk, Trey C Mullikin, William Breen, et al.
Practical Radiation Oncology|February 13, 2022
Development and Internal Validation of a Recursive Partitioning Analysis-Based Model Predictive of Pain Flare Incidence After Spine Stereotactic Body Radiation TherapyRoman O Kowalchuk, Trey C Mullikin, William S Harmsen, et al.
Pageof 12